Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer

被引:86
作者
Birkholz, K. [1 ]
Hombach, A. [2 ]
Krug, C. [1 ]
Reuter, S. [1 ]
Kershaw, M. [3 ]
Kaempgen, E. [1 ]
Schuler, G. [1 ]
Abken, H. [2 ]
Schaft, N. [1 ]
Doerrie, J. [1 ]
机构
[1] Univ Hosp Erlangen, Dept Dermatol, D-91052 Erlangen, Bavaria, Germany
[2] Univ Cologne, CMMC, Cologne, Germany
[3] Peter MacCallum Canc Ctr, Canc Immunol Sect, Melbourne, Vic, Australia
关键词
RNA transfection; retroviral gene transfer; chimeric TCR; immunoreceptor; DENDRITIC CELLS; GENE-THERAPY; HUMAN-BREAST; CLASS-I; RECEPTOR; LYMPHOCYTES; EXPRESSION; ELECTROPORATION; MELANOMA; TCR;
D O I
10.1038/gt.2008.189
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human T lymphocytes can be redirected with a new defined specificity by expression of a chimeric T-cell receptor (immunoreceptor) for the use in adoptive immunotherapy of cancer. Whereas standard procedures use retroviral gene transduction to constitutively express immunoreceptors in T cells, we here explored for the first time mRNA electroporation to achieve transient immunoreceptor expression, and thereby minimizing the risk of persistence of potential autoaggression. CD4(+) and CD8(+) T cells were efficiently transfected with immunoreceptors specific for ErbB2 and CEA. The immunoreceptor expression was transient with half-maximal expression at day 2 and no detectable immunoreceptor expression at day 9 after electroporation. Immunoreceptor-transfected T cells were specifically activated upon coincubation with ErbB2(+) and CEA(+) tumor cells, respectively, resulting in secretion of interferon-gamma (IFN gamma), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF alpha). Furthermore, immunoreceptor-transfected CD8(+) T cells specifically lysed ErbB2(+) and CEA(+) tumor cells, respectively. The RNA-transfected T cells retained their cytotoxic function after 2 days of activation and exhibited cytolytic activities like retrovirally transduced T cells. RNA electroporation of T cells thereby provides a versatile tool for transient immunoreceptor expression, which may be of advantage in avoiding the persistence of unintended auto-aggression. Gene Therapy (2009) 16, 596-604; doi: 10.1038/gt.2008.189; published online 22 January 2009
引用
收藏
页码:596 / 604
页数:9
相关论文
共 46 条
  • [1] [Anonymous], 2006, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol, DOI DOI 10.1200/JCO.2006.05.9964
  • [2] Bolhuis Reinder L. H., 2000, P423
  • [3] Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA
    Bonehill, Aude
    Tuyaerts, Sandra
    Van Nuffel, An Mt
    Heirman, Carlo
    Bos, Tomas J.
    Fostier, Karel
    Neyns, Bart
    Thielemans, Kris
    [J]. MOLECULAR THERAPY, 2008, 16 (06) : 1170 - 1180
  • [4] Safety of retroviral gene marking with a truncated NGF receptor
    Bonini, C
    Grez, M
    Traversari, C
    Ciceri, F
    Marktel, S
    Ferrari, G
    Dinauer, M
    Sadat, M
    Aiuti, A
    Deola, S
    Radrizzani, M
    Hagenbeek, A
    Apperley, J
    Ebeling, S
    Martens, A
    Kolb, HJ
    Weber, M
    Lotti, F
    Grande, A
    Weissinger, E
    Bueren, JA
    Lamana, M
    Falkenburg, JHF
    Heemskerk, MHM
    Austin, T
    Kornblau, S
    Marini, F
    Benati, C
    Magnani, Z
    Cazzaniga, S
    Toma, S
    Gallo-Stampino, C
    Introna, M
    Slavin, S
    Greenberg, PD
    Bregni, M
    Mavilio, F
    Bordignon, C
    [J]. NATURE MEDICINE, 2003, 9 (04) : 367 - 369
  • [5] Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells
    Breckpot, K
    Heirman, C
    Neyns, B
    Thielemans, K
    [J]. JOURNAL OF GENE MEDICINE, 2004, 6 (11) : 1175 - 1188
  • [6] Gene therapy for SCID - a complication after remarkable progress
    Buckley, RH
    [J]. LANCET, 2002, 360 (9341) : 1185 - 1186
  • [7] Butterfield LH, 2003, CLIN CANCER RES, V9, P998
  • [8] The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma
    Cheadle, Eleanor J.
    Gilham, David E.
    Hawkins, Robert E.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (01) : 65 - 68
  • [9] Clay TM, 1999, J IMMUNOL, V163, P507
  • [10] Cooper LJN, 2006, CYTOTHERAPY, V8, P105, DOI 10.1080/14653240600620176